Artificial intelligence (AI) and machine learning are driving a great deal of the healthcare innovation in precision medicine, according to a new Chilmark Research report. The report reveals achieving the full potential of precision medicine is impossible to realize without applying AI and machine learning. Specifically, leveraging advanced machine learning and deep learning technology can rapidly analyze large datasets that outperform clinicians and researchers. Precision Medicine: Making
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Notable Nabs $40M to Expand Drug Discovery Platform for Personalized Oncology
Notable, a San Francisco, CA-based company redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development has raised $40M in Series B funding. The Series B round is co-led by B Capital Group and LifeForce Capital. LifeForce is a returning investor, joined by new investors B Capital and Industry Ventures. This latest round brings Notable’s total funding to over $55M.Notable was founded in 2017 by Matt De Silva after helping his own father Marc, who
Read More
Atomwise, Enamine Launches AI-Powered 10 Billion Compound Virtual Drug Screen for Pediatric Oncology
Atomwise announced the launch of a 10 billion compound AI-powered virtual drug screening initiative for pediatric oncology, in collaboration with Enamine Ltd., the world’s largest chemical supplier. The goal of this initiative – called the 10-to-the-10 program – is to dramatically increase the discovery of safer small molecules to treat pediatric cancers. When completed, it will stand as the largest ever virtual drug screen. 10-to-the-10 Program OverviewCancer is diagnosed in more than 15,000
Read More
Data-Driven Precision Medicine Startup Tempus Lands $200M to Expand Into New Therapeutic Areas
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by T. Rowe Price. With this latest round, the company has raised $520 million since its founding in September 2015.Founded in 2015, Tempus has the largest
Read More
LunaPBC Raises $4.6M to Fuel Community-Owned Genomic & Health Data Platform
LunaPBC, founder of LunaDNA, the first community-owned genomic and health data platform, has raised $4.6 million from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. The latest round brings the company’s total funding to date to $7.6 million.
First Community-Owned Health & DNA Research Platform
Founded in 2017 on the belief that health data sharing and community ownership are the new philanthropy, LunaDNA is the first
Read More
7 Trends Accelerating “TechBio” – The Life Sciences and Computer Sciences Convergence
We are now living in what I’m calling the
TechBio revolution. That’s not a typo that should read BioTech, but rather a
new way of looking at the convergence of technology and biology.
TechBio is defined as an engineering-first approach of biological processes for industrial, and other purposes, especially the genetic manipulation of microorganisms for the production of antibiotics, hormones, and so on. A process that uses AI and data-enabled discovery to complement the exploration of
Read More
Digital Twin Technology: Should Healthcare Jump on the Bandwagon?
While healthcare is known for not jumping to conclusions very fast when investing in new technology, the industry starts to pick up the pace. Such “newcomers” as blockchain, IoT, VR, and AR get a well-deserved appraisal and become an integral part of next-gen custom healthcare software aimed at supporting personalized treatment and predictable patient outcomes across a wide range of conditions.
We anticipate that the digital twin technology has good chances to become the next addition to the
Read More
Why 2018 May Have Been A High-Water Mark for Digital Health Funding
Notwithstanding the quite significant stock market turmoil for publicly traded healthcare companies in recent months, the level of private investment activity continued to be quite strong this past quarter. According to Rock Health, 1Q19 registered just under $1.0 billion of investments made in 61 healthcare technology companies, which while below the trailing two year quarterly average of $1.4 billion, still suggests an annual investment pace running toward $4.0 billion. StartUp Health, which
Read More
Medidata Launches New Life Sciences Company, Acorn AI
Life sciences digital transformation company Medidata, today announced the launch of Acorn AI, a new company designed to provide actionable insights across the entire drug continuum – from R&D to commercialization. In addition, the company has appointed Rama Kondru, Ph.D., as the chief information officer for Medidata and Acorn AI’s first CIO to lead the company’s enterprise data strategy, architecture and future platform development – all helping the company to accelerate the creation of
Read More
AdoRx Therapeutics, J&J Team Up to Develop Novel Lung Cancer Therapeutics
AdoRx Therapeutics, a UK based drug discovery company, and Johnson & Johnson are teaming up to develop novel therapeutics for the treatment of lung cancer. As part of the strategic collaboration, AdoRx has granted an exclusive option to research, develop and commercialize novel antagonists within the AdoRx portfolio, and the groups will collaborate on drug discovery and preclinical development activities. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on
Read More
